KLP Kapitalforvaltning AS Has $241,000 Stock Position in ANI Pharmaceuticals, Inc. $ANIP

KLP Kapitalforvaltning AS grew its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 23.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,700 shares of the specialty pharmaceutical company’s stock after purchasing an additional 700 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in ANI Pharmaceuticals were worth $241,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ANIP. GAMMA Investing LLC raised its stake in ANI Pharmaceuticals by 163.8% during the 1st quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company’s stock worth $95,000 after buying an additional 881 shares during the period. Allspring Global Investments Holdings LLC grew its holdings in ANI Pharmaceuticals by 53.3% during the first quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company’s stock worth $599,000 after purchasing an additional 3,112 shares during the period. Decker Retirement Planning Inc. bought a new position in ANI Pharmaceuticals during the first quarter worth about $1,805,000. Lisanti Capital Growth LLC grew its holdings in ANI Pharmaceuticals by 291.8% during the first quarter. Lisanti Capital Growth LLC now owns 105,425 shares of the specialty pharmaceutical company’s stock worth $7,058,000 after purchasing an additional 78,515 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in ANI Pharmaceuticals by 68.3% during the first quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company’s stock worth $10,565,000 after purchasing an additional 64,021 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 0.3%

NASDAQ ANIP opened at $95.12 on Tuesday. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $99.50. The company has a 50 day moving average of $92.90 and a 200-day moving average of $75.08. The company has a market cap of $2.06 billion, a price-to-earnings ratio of -123.53 and a beta of 0.58.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, June 8th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter. The firm had revenue of $64.48 million during the quarter. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. On average, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Wall Street Zen upgraded ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a “buy” rating in a research report on Monday, September 8th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, October 8th. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. Finally, Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $99.14.

Insider Buying and Selling

In related news, Director Matthew J. Leonard sold 2,528 shares of the business’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $90.62, for a total value of $229,087.36. Following the sale, the director owned 6,864 shares of the company’s stock, valued at $622,015.68. The trade was a 26.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Muthusamy Shanmugam sold 52,988 shares of the company’s stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $90.44, for a total transaction of $4,792,234.72. Following the transaction, the chief operating officer owned 431,920 shares in the company, valued at $39,062,844.80. This represents a 10.93% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 413,830 shares of company stock valued at $36,505,378 over the last quarter. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.